The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
Abstract
Purpose: To assess the efficacy and safety of S-1, a novel oral fluoropyrimidine derivative, we conducted a multicenter late phase II study in patients with advanced gastric cancer. Patients and Methods: Fifty-one patients who had received no previous chemotherapy were enrolled. Fifty patients were eligible for efficacy and safety analyses. The overall response was evaluated for the 43 patients who had metastatic lesions. S-1 was administered orally after breakfast and dinner for 28 days, followed by a 14-day break. The dosages were assigned according to the patients’ body surface area (BSA): BSA <1.25 m 2, 40 mg; 1.25–1.5 m 2, 50 mg, and BSA ≥1.5 m 2, 60 mg, twice daily. Results: The overall response to treatment was evaluated as partial response in 19 of the 43 patients (44%; 95% confidence interval 30–59%). The median survival time in all patients was 207 days with 1- and 2-year survival rates of 36.0 and 14.0%, respectively. Grade 3 adverse reactions included decreased hemoglobin values in 2 patients, leukopenia, neutropenia and diarrhea in 1 patient each. No other grade 4 or unexpected adverse reactions were seen. Conclusions: S-1 is effective against advanced gastric cancer. This oral treatment is suitable for outpatients because of its mild toxicity. Further therapeutic benefits are likely to be obtained by combining S-1 with other chemotherapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Shirasaka, T., Shimamato, Y., Ohshimo, H., Yamaguchi, M., Kato, T., Yonekura, K., & Fukushima, M. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199607000-00010 · Cited by 820
Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., & Fryer, J. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.425 · Cited by 773
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.
Heggie, G. D., Sommadossi, J., Cross, D. S., Huster, W. J., & Diasio, R. B. (1987) · PubMed · Cited by 722
Sakata, Y., Ohtsu, A., Horikoshi, N., Sugimachi, K., Mitachi, Y., & Taguchi, T. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00211-1 · Cited by 565
THE SYNTHESIS OF 5-FLUOROPYRIMIDINES
Duschinsky, R., Pleven, E., & Heidelberger, C. (1957) · Journal of the American Chemical Society · doi:10.1021/ja01573a087 · Cited by 510
Seifert, P., Baker, L. H., Reed, M. L., & Vaitkevicius, V. K. (1975) · Cancer · doi:10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c · Cited by 420
MACDONALD, J. S., SCHEIN, P. S., WOOLLEY, P. V., SMYTHE, T., UENO, W., HOTH, D., SMITH, F., BOIRON, M., GISSELBRECHT, C., BRUNET, R., et al. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-533 · Cited by 351
Shirasaka, T., Shimamoto, Y., & Fukushima, M. (1993) · PubMed · Cited by 348
Tatsumi, K., Fukushima, M., Shirasaka, T., & Fujii, S. (1987) · PubMed · Cited by 260
Cited by
Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T., Nashimoto, A., Fujii, M., Nakajima, T., & Ohashi, Y. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5908 · Cited by 1,434
Boku, N., Yamamoto, S., Fukuda, H., Shirao, K., Doi, T., Sawaki, A., Koizumi, W., Saito, H., Yamaguchi, K., Takiuchi, H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70259-1 · Cited by 586
Self-citationYamanaka, T., Matsumoto, S., Teramukai, S., Ishiwata, R., Nagai, Y., & Fukushima, M. (2007) · Oncology · doi:10.1159/000127412 · Cited by 454
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review
Malet-Martino, M., & Martino, R. (2002) · The Oncologist · doi:10.1634/theoncologist.7-4-288 · Cited by 382
Catalano, V., Labianca, R., Beretta, G. D., Gatta, G., de Braud, F., & Van Cutsem, E. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.004 · Cited by 365
Metadata
- Authors
- Koizumi, W., Kurihara, M., Nakano, S., & Hasegawa, K.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2000
- Volume
- 58
- Issue
- 3
- Pages
- 191-197
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2008575122
- Cited by
- 440
- References
- 17
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer. https://app.cochat.ai/papers/10.1159/000012099
- The paper
- Koizumi, W., Kurihara, M., Nakano, S., & Hasegawa, K. (2000). Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer. Oncology. https://doi.org/10.1159/000012099
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
